Alto Neuroscience, Inc. ANRO
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About ANRO
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Alto Neuroscience, Inc. (NYSE: ANRO) is a clinical-stage biotechnology company focused on developing precision psychiatry treatments for mental health conditions such as major depressive disorder (MDD), bipolar depression, schizophrenia, and post-traumatic stress disorder (PTSD). The company operates within the biotechnology and central nervous system (CNS) therapeutics industries, emphasizing biomarker-driven drug development intended to match patients with therapies based on measurable biological and neurophysiological characteristics. Its primary revenue and enterprise value drivers are tied to the advancement of its clinical-stage pipeline, intellectual property portfolio, and strategic development capabilities rather than commercialized products.
Alto Neuroscience was founded in 2019 by psychiatrist and neuroscientist Dr. Amit Etkin, who previously led research efforts at Stanford University focused on neurobiology and psychiatric disorders. The company evolved around the concept that psychiatric drug development could achieve improved clinical outcomes through patient stratification using biomarkers such as electroencephalography (EEG), neurocognitive assessments, digital phenotyping, and other objective measures. Alto completed its initial public offering in 2024 and has positioned itself as a precision medicine-focused CNS developer seeking differentiation from traditional psychiatry drug companies that rely on broader population-based clinical approaches.
Business Operations
Alto Neuroscience operates primarily through a single biotechnology business focused on discovering, developing, and clinically evaluating neuropsychiatric therapeutics. Its development programs include candidates such as ALTO-100 for major depressive disorder associated with cognitive impairment, ALTO-300 targeting biomarker-defined depression populations, ALTO-203 for treatment-resistant depression, and additional CNS-focused assets across mood and psychiatric disorders. The company generates no recurring commercial revenue as of publicly available filings and instead finances operations primarily through equity offerings, investor capital, and collaborations.
The company’s operational model combines drug development with proprietary biomarker analytics intended to identify patient subgroups most likely to benefit from treatment candidates. Alto utilizes clinical data platforms, neurophysiological testing methods, and machine learning-supported analyses to support trial enrollment and therapeutic targeting. Operations are concentrated in the United States, though clinical activities may involve international trial sites and contract research organizations. Alto also works with external manufacturing, research, and development partners to support clinical trials and drug production, which is common among clinical-stage biotechnology firms.
Strategic Position & Investments
Alto Neuroscience’s strategic direction centers on advancing precision psychiatry through biomarker-guided clinical development. The company has emphasized building a diversified pipeline composed of both internally developed compounds and externally sourced or licensed assets. Its strategy focuses on reducing clinical trial variability in psychiatric drug development by identifying biologically defined patient populations, an approach intended to improve efficacy outcomes and differentiate Alto within the CNS therapeutics market.
The company has invested significantly in biomarker infrastructure, data science capabilities, and clinical platform technologies supporting patient stratification. Alto’s pipeline includes compounds targeting glutamatergic, GABAergic, and other neuropsychiatric mechanisms associated with mood and cognitive disorders. Public filings and investor materials indicate ongoing investment in precision neuropsychiatry methodologies and clinical-stage advancement rather than large-scale acquisitions or diversified subsidiary holdings. Data reviewed from public disclosures did not indicate material operating subsidiaries of significant scale beyond core corporate entities.
Geographic Footprint
Alto Neuroscience is headquartered in Los Altos, California, and its primary operational activities are concentrated in the United States. The company conducts research, corporate administration, and strategic development activities domestically while utilizing distributed clinical trial infrastructure to support its development programs. As a clinical-stage biotechnology company, Alto’s geographic footprint is narrower than that of large multinational pharmaceutical firms.
The company’s market and investor presence expanded following its public listing on the New York Stock Exchange under the ticker symbol ANRO. Clinical development activities may involve partnerships with global contract research organizations and trial sites in multiple regions depending on study requirements. However, available public disclosures indicate that Alto’s operational influence remains primarily North American, with international exposure tied mainly to research and clinical development support functions rather than commercial operations.
Leadership & Governance
Alto Neuroscience was founded by Dr. Amit Etkin, whose academic and clinical research background in psychiatry and neuroscience helped shape the company’s precision medicine strategy. Leadership has consistently emphasized biomarker-guided psychiatry development, data-driven patient selection, and translational neuroscience as central components of corporate strategy. Governance and operational direction are informed through biotechnology, neuroscience, pharmaceutical development, and capital markets expertise reflected in the executive team and board composition.
Key executives identified in public filings and company disclosures include:
- Amit Etkin – Founder and Chief Executive Officer
- Scott Garland – Chief Financial Officer
- David J. Hough – Chief Medical Officer
- Rick Soni – Chief Operating Officer
- Ian Massey – Chief Business Officer
Public disclosures, including SEC filings, investor presentations, and exchange registration materials, consistently describe the company’s leadership philosophy as focused on transforming psychiatric treatment through precision medicine approaches and biomarker-enabled therapeutic development.